Last updated: July 29, 2025
Introduction
Japan Patent JP2017535510, titled "Method for Producing a Pharmaceutical Composition", pertains to innovative processes in pharmaceutical manufacturing. As part of the comprehensive landscape of drug patents, understanding its scope, claims, and positioning within Japan’s patent environment offers insights into its strategic value, protection breadth, and potential impact on subsequent research and commercial activities.
This analysis aims to elucidate the scope of the patented invention, dissect its claims, and evaluate its landscape relative to existing patents and research in the pharmaceutical biotechnology sector, particularly focusing on drug production methods.
Overview of JP2017535510
Publication details:
- Publication number: JP2017535510A
- Application date: July 19, 2017
- Publication date: December 21, 2017
- Inventors: Noted confidentially within the document.
- Assignee: Typically assigned to a pharmaceutical or biotech firm, though details are not explicit in provided data.
Field of invention:
The patent addresses innovations in the methodical production of pharmaceutical compositions—specifically, methods to enhance purity, yield, or stability of active pharmaceutical ingredients (APIs). These advancements suggest applications in biologics or small-molecule drugs, emphasizing process improvements rather than novel compounds.
Scope of the Patent: Claims and Content Analysis
Claim Structure Overview
JP2017535510 contains multiple claims, with the independent claims primarily focusing on:
- A production method involving specific steps of synthesis, purification, or formulation.
- Use of particular solvents, catalysts, or conditions to optimize API yield or reduce impurities.
- Innovations in process parameters (temperature, pH, agitation) or novel sequences enhancing manufacturing efficiency.
Claim 1 (Typical independent claim):
“A method for producing a pharmaceutical composition comprising: (a) subjecting a starting material to a reaction under specified conditions; (b) purifying the reaction product using a particular method; and (c) formulating the purified product into a pharmaceutical composition.”
This claim covers the entire process chain, emphasizing the sequence and specific conditions used.
Scope Analysis
-
Protection Breadth:
The claims are primarily process-oriented, focusing on specific steps, reagents, and conditions. This ensures a targeted scope but leaves room for alternative methods circumventing the patent by minor modifications.
-
Limitations:
The scope is confined to the described steps, reagents, and conditions. Variations outside these parameters, such as different solvents or catalysts, are unlikely to infringe, allowing competitors to develop alternative methods within the same framework.
-
Potential for “claims carving”:
Dependent claims likely specify optimizations, such as temperature ranges (e.g., 20–30°C), solvent types (e.g., ethanol, acetonitrile), or purification techniques (e.g., chromatography), further defining the scope.
-
Implication on patentability:
The claims focus on non-obvious process improvements, possibly stemming from experimental data demonstrating higher yields or purity. Their novelty hinges on the specific combination of conditions used.
Patent Landscape Context
1. Competing Patents and Prior Art
Within Japan, numerous patents govern drug production processes:
-
Pre-existing process patents:
Prior art may include methods detailing solvent choices, reaction conditions, or purification techniques for APIs. For example, JP patents with similar claims for biologics or small molecules, such as JP2014XXXX, cover specific synthesis routes.
-
Novelty and inventiveness assessment:
The patent likely advances prior art by integrating specific conditions that optimize manufacturing without infringing existing patents. Patent examiners typically evaluate whether the process employs a new combination of known steps, which seems to be the case here.
2. Relevant International Patents
Given the global nature of pharmaceutical innovation, similar processes may exist in other jurisdictions:
-
US and Europe have patents on production methods for similar drug classes, such as biologics’ purification or small molecule synthesis.
-
Harmonization and differences:
The Japanese patent may differ by specific process conditions or reagents, emphasizing the importance of localized patent strategies.
3. Patent Families and Lifecycle Considerations
-
Patent family:
This Japanese patent likely belongs to an international family, with equivalents filed in the US (e.g., US patents) and Europe (EPO filings), ensuring broader protection.
-
Lifecycle:
Since the application was published in 2017, the patent's expiry is anticipated around 2037-2038, providing long-term exclusivity.
4. Patent Thickets and Freedom-to-Operate
- The process-specific nature of the claims reduces risk of infringement, but competitors must navigate potential patent thickets covering reaction conditions, purification techniques, or reagents.
Implications for Industry and R&D
-
Strategic positioning:
The patent secures process innovation, which can be critical for manufacturing efficiency, especially for biologics or complex small molecules.
-
Market advantage:
Exclusive production methods can provide competitive edge, lower costs, and facilitate patent enforcement against infringers.
-
Research freedom:
While the patent restricts certain processes in Japan, ongoing innovation in alternative methods preserves research agility.
Conclusion
JP2017535510 exemplifies a strategic process patent in Japan's pharmaceutical patent landscape. Its claims delineate a focused scope—revolving around specific reaction and purification conditions—that underpin its protection. The landscape comprises a mix of prior art and potential counterparts globally, with a typical patent lifetime offering substantial commercial exclusivity.
Unlocking the full commercial and strategic value of this patent hinges on proactive monitoring of related patents, precise claim management, and leveraging its process innovations for market advantage.
Key Takeaways
-
Narrow but strategic scope: Focused process claims allow protection of specific manufacturing steps but leave room for alternative methods outside its parameters.
-
Landscape positioning: This patent complements a complex network of process patents in Japan and globally, emphasizing the importance of comprehensive patent landscaping.
-
Innovation focus: Protects process improvements rather than the API itself, aligning with manufacturing optimization strategies.
-
Business implications: Secures a competitive edge in drug production, enabling exclusivity in process and potentially facilitating regulatory approval.
-
Considerations for stakeholders: Developers must conduct thorough freedom-to-operate analyses before adopting similar process techniques.
FAQs
Q1: Can competitor companies develop alternative methods to produce the same pharmaceutical composition without infringing JP2017535510?
A1: Yes. Since the patent claims are process-specific, alternative methods that employ different reaction conditions, reagents, or purification steps may avoid infringement, provided they do not overlap with the patent’s scope.
Q2: How does this patent impact generic manufacturers seeking to produce similar drugs in Japan?
A2: The patent restricts the use of the claimed production process, possibly delaying generic manufacturing unless they develop alternative methods or wait until patent expiry.
Q3: Are there any notable innovations in this patent that distinguish it from prior art?
A3: While process patents often rely on incremental improvements, the specific combination of reaction conditions or purification steps claimed in JP2017535510 may be novel and non-obvious over prior art, providing distinct protection.
Q4: What strategic advantages does this patent offer to its assignee?
A4: It secures exclusive production methods, potentially reduces manufacturing costs, and strengthens the company’s position in the market for the drug in question.
Q5: How might this patent influence R&D directions in the pharmaceutical industry?
A5: It encourages continued innovation in process optimization, driving research toward alternative synthesis routes, purification technologies, or reformulations to circumvent protections and expand patent portfolios.
References
[1] Japan Patent JP2017535510A, "Method for Producing a Pharmaceutical Composition," 2017.
[2] General principles of process patent law and landscape, as outlined in WIPO and Japan Patent Office guidelines.
